Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
Cancer Medicine · 2025
DOI: 10.1002/cam4.70734 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Qingyang Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liping Dou.
Abstract (Originalsprache)
Introduction
Currently, there are only a few avaailable treatment options for patients with relapsed and refractory acute myeloid leukemia (R/R AML).
Methods
We conducted a single‐center, phase 1 prospective study (ChiCTR2200065634) to evaluate the efficacy and safety of chidamide, demethylating drugs (azacitidine), cytarabine, aclacinomycin, and G‐CSF plus venetoclax (CDCAG‐VEN) in patients with R/R AML. The previous CDCAG regimen was used as a historical control to compare its efficacy and safety. Thirty and 22 patients received one course of CDCAG with or without a 14‐day course of venetoclax, respectively.
Results
The overall response rate (ORR) was significantly higher in the CDCAG‐VEN group than in the CDCAG‐treated group (78.6% vs. 45.5%; p = 0.015), and the CDCAG‐VEN group achieved a better trend of measurable residual disease‐negative response (61.1% vs. 22.2%, p = 0.134). Compared with the CDCAG group, the CDCAG‐VEN group exhibited significantly better 1‐year overall survival (63.3% vs. 35.1%, p = 0.005) and progression‐free survival (76.7% vs. 36.0%, p = 0.022). The duration of response was notably better in the CDCAG‐VEN group than in the CDCAG group (71.2% vs. 34.3%, p = 0.021) and had a lower cumulative incidence of relapse (22.2% vs. 48.9%, p = 0.095). The neutrophil and platelet recovery times were similar between the CDCAG‐VEN and CDCAG groups (neutrophil: 18 days vs. 19 days, p = 0.293; platelet: 18 days vs. 19 days, p = 0.311). The frequencies of adverse events were comparable between both groups, except for a lower incidence of thrombosis in the CDCAG‐VEN group (0% vs. 22.7%, p = 0.006).
Discussion
In conclusion, venetoclax in combination with CDCAG is an effective and safe treatment regimen for R/R AML, thereby rapidly identifying chemosensitive patients and inducing measurable residual disease‐negative remission in a high proportion of patients with R/R AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- Medical School of Chinese PLA, Beijing, China.
ORCID-Profile: Qingyang Liu
Förderung
- Liping Dou
Zitieren
APA
Liu, Q., Zhang, X., Lv, L., Xu, L., Jing, Y., Gao, W., Wang, L., & Dou, L. (2025). Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia. Cancer Medicine. https://doi.org/10.1002/cam4.70734
Vancouver
Liu Q, Zhang X, Lv L, Xu L, Jing Y, Gao W, et al. Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia. Cancer Medicine. 2025. doi:10.1002/cam4.70734
BibTeX
@article{Liu2025,
author = {Liu, Qingyang and Zhang, Xiawei and Lv, Lei and Xu, Linming and Jing, Yu and Gao, Wenjing and Wang, Lili and Dou, Liping},
title = {Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70734}
}
EUVIMED